Simplify Asset Management Inc. Takes Position in TG Therapeutics, Inc. (NASDAQ:TGTX)

Simplify Asset Management Inc. purchased a new position in shares of TG Therapeutics, Inc. (NASDAQ:TGTX - Free Report) in the fourth quarter, according to the company in its most recent Form 13F filing with the SEC. The fund purchased 11,237 shares of the biopharmaceutical company's stock, valued at approximately $338,000.

Several other institutional investors and hedge funds have also modified their holdings of the business. Bleakley Financial Group LLC bought a new stake in shares of TG Therapeutics during the 4th quarter valued at approximately $245,000. Castellan Group acquired a new position in shares of TG Therapeutics during the fourth quarter worth $8,539,000. Segall Bryant & Hamill LLC bought a new position in shares of TG Therapeutics in the 3rd quarter valued at $1,225,000. Barclays PLC boosted its holdings in shares of TG Therapeutics by 83.9% during the 3rd quarter. Barclays PLC now owns 347,057 shares of the biopharmaceutical company's stock valued at $8,117,000 after acquiring an additional 158,323 shares in the last quarter. Finally, JPMorgan Chase & Co. boosted its holdings in shares of TG Therapeutics by 60.0% during the 3rd quarter. JPMorgan Chase & Co. now owns 720,798 shares of the biopharmaceutical company's stock valued at $16,859,000 after acquiring an additional 270,286 shares in the last quarter. 58.58% of the stock is currently owned by institutional investors.

TG Therapeutics Trading Down 1.4 %

Shares of NASDAQ TGTX traded down $0.59 during trading on Thursday, reaching $40.20. The company had a trading volume of 1,308,186 shares, compared to its average volume of 2,982,078. The company's fifty day moving average price is $34.17 and its 200-day moving average price is $30.18. The company has a quick ratio of 3.91, a current ratio of 4.59 and a debt-to-equity ratio of 1.27. The stock has a market cap of $6.31 billion, a P/E ratio of -401.96 and a beta of 2.30. TG Therapeutics, Inc. has a 12 month low of $12.93 and a 12 month high of $43.32.

Remove Ads

TG Therapeutics (NASDAQ:TGTX - Get Free Report) last released its earnings results on Monday, March 3rd. The biopharmaceutical company reported $0.15 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.08 by $0.07. TG Therapeutics had a negative net margin of 5.42% and a negative return on equity of 8.32%. The business had revenue of $108.19 million for the quarter, compared to analyst estimates of $100.67 million. As a group, research analysts expect that TG Therapeutics, Inc. will post 0.08 earnings per share for the current year.

Analyst Upgrades and Downgrades

A number of brokerages have issued reports on TGTX. HC Wainwright reaffirmed a "buy" rating and issued a $55.00 target price on shares of TG Therapeutics in a report on Tuesday, March 4th. StockNews.com raised TG Therapeutics from a "sell" rating to a "hold" rating in a research note on Tuesday, March 4th. Two investment analysts have rated the stock with a hold rating and five have assigned a buy rating to the company. According to MarketBeat.com, TG Therapeutics currently has a consensus rating of "Moderate Buy" and an average price target of $40.67.

Insider Transactions at TG Therapeutics

In other TG Therapeutics news, CFO Sean A. Power sold 10,021 shares of TG Therapeutics stock in a transaction on Monday, January 6th. The shares were sold at an average price of $28.53, for a total value of $285,899.13. Following the completion of the sale, the chief financial officer now directly owns 660,611 shares of the company's stock, valued at approximately $18,847,231.83. The trade was a 1.49 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Insiders own 10.50% of the company's stock.

TG Therapeutics Profile

TG Therapeutics, Inc, a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases in the United States and internationally. It provides BRIUMVI, an anti-CD20 monoclonal antibody for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease in adults.